Results 91 to 100 of about 5,711,116 (385)

Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: A nested case-control study [PDF]

, 2014
Vitamin D pathway single nucleotide polymorphisms (SNPs) are potentially useful proxies for investigating whether circulating vitamin D metabolites [total 25-hydroxyvitamin-D, 25(OH)D; 1,25-dihydroxyvitamin, 1,25(OH)2D] are causally related to prostate ...
Bonilla, Carolina, Donovan, Jenny L., Evans, David M., Fraser, William D., Gilbert, Rebecca, Hamdy, Freddie C., Kemp, John P., Lane, J. Athene, Lathrop, Mark, Lewis, Sarah, Martin, Richard M., Metcalfe, Chris, Neal, David E., Smith, George Davey   +13 more
core   +3 more sources

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

Diagnostics, 2020
Radical prostatectomy (RP) is a curatively intended treatment option for clinically localized non-metastatic prostate cancer (PCa). Novel biomarkers could refine treatment choice based on a better identification of men at risk of biochemical recurrence ...
Hein Vincent Stroomberg, Gitte Kristensen, Kasper Drimer Berg, Solvej Lippert, Klaus Brasso, Martin Andreas Røder   +5 more
doaj   +1 more source

Rapid progression of prostate cancer in men with a BRCA2 mutation. [PDF]

, 2008
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients.
Ainsworth, Peter, Armel, S, Bellati, Christina, Couch, F, Cummings, S, Daly, Mary, Danquah, Jessica, Domchek, Susan, Eisen, Andrea, Foulkes, WD, Garber, Judy, Ghadirian, P, Gilchrist, Dawna, Hereditary Breast Cancer Study Group, Horsman, Douglas, Isaacs, Claudine, Karlan, Beth, Kim-Sing, Charmaine, Lynch, HT, Manoukian, Siranoush, Maugard, Christine, McKinnon, Wendy, Meschino, Wendy, Nam, R, Narod, SA, Nedelcu, Raluca, Neuhausen, S, Olopade, O, Pasini, Barbara, Poll, A, Saal, H, Stoppa-Lyonnet, D, Sun, P, Tulman, A, Tung, Nadine, Vichodez, G, Wagner, T, Warner, E, Weitzel, J, Wood, Marie   +39 more
core  

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Survival outcomes in men with a positive family history of prostate cancer: a registry based study

BMC Cancer, 2020
Background To investigate the correlation between family history of prostate cancer (PCa) and survival (overall and cancer specific) in patients undergoing treatment for PCa.
Mann Ang, Martin Borg, Michael E. O’Callaghan, for the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC)   +3 more
doaj   +1 more source

The incidence of prostate cancer in Iran: Results of a population-based cancer registry [PDF]

, 2007
Background: Little is known about the epidemiology of prostate cancer in Iranian men. We carried out an active prostate cancer surveillance program in five provinces of Iran.
Alimohammadian, M., Babai, M., Darvish-Moghadam, S., Fakheri, H., Ghorbani, A., Mansour-Ghanaei, F., Mohagheghi, M.A., Nooraie, M., Sadjadi, A., Semnani, S., Zahedi, M.J.   +10 more
core  

Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative. [PDF]

, 2017
BackgroundEvidence suggests that risk of colorectal and prostate cancer is increased among those with a family history of the same disease, particularly among first-degree relatives.
Beebe-Dimmer, Jennifer L, Bock, Cathryn H, Lane, Dorothy, Nassir, Rami, Palmer, Nynikka RA, Paskett, Electra, Schwartz, Ann G, Simon, Michael S, Yee, Cecilia   +8 more
core   +2 more sources

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source

State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer [PDF]

European Medical Journal Oncology, 2014
Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the understanding of castration-resistant PrCa which has led to the development of new drugs that have an impact
Elena Castro, Nuria Romero, David Olmos
doaj